Abstract:RNAs with 5′‐triphosphate (ppp) are detected in the cytoplasm principally by the innate immune receptor RIG‐I, whose activation triggers a Type I interferon response. Cellular RNAs undergo post‐transcriptional modifications which ensures that self RNAs do not carry 5′ppp and/or blunt‐ends. We carried out a thorough biochemical characterization of RIG‐I complexes with RNAs carrying various end‐modifications as well as measured the effect of these end‐modifications on their signaling activity. We find that discrimination of RNA ligands occurs at multiple stages and signaling RNAs have high affinity and ATPase turnover rate and thus a high k atpase / K d . Our studies reveal that the autoinhibitory interface between CARD2 (second CARD) and Hel2i (Helicase 2 insertion domain) plays a critical role in RNA selectivity, wherein this interface acts as a “gate” that prevents cellular RNAs from generating productive complexes that can signal. It is thought that self RNAs like mRNAs are not recognized by RIG‐I because 5′ppp is capped by the addition of a 7‐methyl guanosine (m7G) (Cap‐0) and the 5′‐end nucleotide ribose is 2′‐O‐methylated (Cap‐1). We provide a structural and mechanistic basis for the exact roles of capping and 2′‐O‐methylation in evading RIG‐I recognition using enzymatic assays, X‐ray crystallography and cell‐based signaling studies. Surprisingly, we find that Cap‐0 and 5′ppp dsRNA have similar binding affinities, activate RIG‐I's ATPase to the same extent, and shows the same cellular signaling response. Three new crystal structures of RIG‐I complexes with dsRNA bearing 5′OH, 5′ppp, and 5′Cap‐0 reveal that RIG‐I accommodates m7G in a cavity created through conformational changes in helicase‐motif IVa without perturbing the triphosphate interactions. In contrast, Cap‐1 modifications abrogate RIG‐I signaling through a mechanism involving the H830 residue, wherein 2′‐O‐methylation works synergistically with m7G capping to weaken RNA affinity and ATPase activity. Our work provides new structural insights into the host and viral immune evasive mechanisms from RIG‐I explaining the complexity of cap structures over evolution. Support or Funding Information This work was supported by NIH grant GM111959 to Joseph Marcotrigiano and Smita S Patel.

SP110 sequestration of SP100 protects against toxic filaments during innate immune signaling

Identification of proteins interacting with human SP110 during the process of viral infections.

An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells

Role and Fate of SP100 Protein in Response to Rep-dependent Nonviral Integration System

Functional Dissection of an Innate Immune Response by a Genome-Wide RNAi Screen

Schlafen-11 and -9 are innate immune sensors for intracellular single-stranded DNA

A ZBP1 isoform blocks ZBP1-mediated cell death

Structural and Mechanistic Basis for Self Versus Non‐self RNA Discrimination by the Innate Immune Receptor RIG‐I

Chromatin Regulator SMARCA4 Is Essential for MHV-Induced Inflammatory Cell Death, PANoptosis

A shorter splicing isoform antagonizes ZBP1 to modulate cell death and inflammatory responses

PANoptosome signaling and therapeutic implications in infection: central role for ZBP1 to activate the inflammasome and PANoptosis

Z-DNA binding protein 1 orchestrates innate immunity and inflammatory cell death

An ancient defense system eliminates unfit cells from developing tissues during cell competition

Protein supersaturation powers innate immune signaling

Sp100 Interacts with Phage ΦC31 Integrase to Inhibit Its Recombination Activity.

Structural basis of CRISPR-SpyCas9 inhibition by an anti-CRISPR protein

The SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity

Pathogenic proteotoxicity of cryptic splicing is alleviated by ubiquitination and ER-phagy

Chaperone- and PTM-mediated activation of IRF1 tames radiation-induced cell death and the inflammatory response

Toxin-antitoxin RNA pairs safeguard CRISPR-Cas systems

STING an essential trigger of DNA-mediated innate immune signaling. (P1258)